Evotec commits ~11% Exscientia shares to Recursion deal; total committed ~53%

RECURSION PHARMACEUTICALS, INC.

Evotec SE, holding ~11% of Exscientia shares, executed irrevocable undertaking on Aug 28 to vote in favor of Recursion acquisition.
Combined with prior undertakings from August 8, shareholders holding ~53% of Exscientia now committed to support the deal.
The transaction is structured as a scheme of arrangement under UK Companies Act, with Recursion acquiring all Exscientia share capital.
Irrevocable undertaking prohibits Evotec from accepting competing offers or taking actions that impede the deal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.